MIT team tailors cell jackets to prevent cancer

January 21, 2002

CAMBRIDGE, Mass.--MIT scientists wielding molecular scissors have shown for the first time that the sugar jackets of cancer cells can be tailored to inhibit tumors. The work, which could lead to drugs that attack cancer cells in a very specific manner, will be reported in the January 22, 2002 issue of the Proceedings of the National Academy of Sciences.

The web of material that surrounds every cell, known as the extracellular matrix, is critical to cell function, orchestrating how signals from outside the cell are processed and perceived by it. The key components of that web are complex sugars and proteins.

Scientists have made substantial progress in understanding web proteins and their roles, leading to exciting new drugs like the anti-cancer endostatin, but insights into the sugars have lagged. That's because the sugars are more complex and have many more building blocks than DNA or proteins, making them more difficult to study. New tools developed at MIT, however, are changing that.

Accompanying the MIT paper is a commentary by Professor Ajit Varki of the University of California, San Diego, titled "Six Blind Men and the Elephant - the Many Faces of Heparan Sulfates." Heparan sulfates are the sugars found in cell jackets.

SUGARS AND CANCER

In the current work MIT scientists led by Associate Professor Ram Sasisekharan of the Division of Bioengineering and Environmental Health (BEH) used the new tools to probe the relationship between changes in tumor cells' sugar jackets and cancer. Were the sugars associated with different stages of cancer directly responsible for tumor growth, or simply byproducts?

To find out, Sasisekharan and colleagues isolated two distinct sets of these sugars via molecular scissors, or enzymes, that clip the cell's sugar jacket in different places, resulting in different sugar fragments. The enzyme heparinase I [hep I] created the first kind of sugar; heparinase III [hep III] the second.

The researchers were astonished by what happened when they injected either hep I, hep III, or their respective sugar fragments into mice with cancer. Injection of hep I or its sugar fragment promoted tumor growth, while hep III or its product dramatically inhibited growth. The two similarly influenced tumor metastasis and the growth of blood vessels.

"We were fascinated by the discovery that the tumor cell's sugar coat contains sugar sequences that can both promote and inhibit growth," said Sasisekharan, whose coauthors are BEH Research Affiliates Dongfang Liu and Yosuf El Shabrawi; BEH Postdoctoral Associate Zachary Shriver; and Ganesh Venkataraman, a research associate affiliated with BEH and the Harvard-MIT Division of Health Sciences and Technology.

BALANCING ACT

It is possible that during cancer, tumor cells wear sugar jackets that enable them to either be dormant or rapidly grow and support tumor progression. Cancer could therefore depend on a kind of biological balancing act. "Tumors might be kept in check by the body's production of specific enzymes that in turn release sugar fragments that keep tumor cells dormant. Or, perhaps in response to pathophysiological changes, a tumor cell releases different enzymes that enable the tumor to grow more rapidly," Sasisekharan explained.

In their PNAS paper, the scientists report additional studies in which they explored exactly how the sugar fragments act on cancer cells. Their conclusion: the fragments bind to and therefore affect the activity of specific signaling molecules involved in tumor activity.

The overall work has implications for future cancer drugs. "These findings suggest that the sugar coat worn by tumor cells, which varies according to tissue type, may provide a tissue-specific target for new anti-cancer therapies," according to PNAS.

KEY TOOLS

The current results could not have been achieved without the new tools developed at MIT. A key example is a technique to determine the linear order of building blocks in complex sugars (see MIT Tech Talk, Oct. 20, 1999). "Once you have the sequence of building blocks for a given polysaccharide, you can start cracking the biological function of that sugar in the tissue," explained Sasisekharan. Similar sequencing techniques for DNA and proteins have been instrumental in shaping the biotechnology industry.

Together the MIT tools "allowed us to not only characterize the sugar fragments [reported in PNAS], but to experimentally tilt their balance in the cell," Sasisekharan said.
-end-
The work was supported by the Burroughs Wellcome Foundation, the Arnold and Mabel Beckman Foundation, the National Institutes of Health, the CapCure Foundation, and the Whitaker Health Sciences Foundation.

Copies of the article are available to reporters from the PNAS news office, tel. 202-334-2138, or email pnasnews@nas.edu.

CONTACT: Elizabeth Thomson, MIT News Office, Phone: 617-258-5402, Email: thomson@mit.edu or Dr. Ram Sasisekharan, Phone: 617-258-9494, Email: rams@MIT.EDU

Photo available through MIT News Office, 617-253-2700

Massachusetts Institute of Technology

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.